Synthesis and biological evaluation of a new series of 1-aryl-3-[4-(pyridin-2-ylmethoxy)phenyl]urea derivatives as new anticancer agents

[1]  Liang Cheng,et al.  Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine , 2017, Modern Pathology.

[2]  Chun Hu,et al.  Design, synthesis and cytotoxic evaluation of a novel series of benzo[d]thiazole-2-carboxamide derivatives as potential EGFR inhibitors , 2017, Medicinal Chemistry Research.

[3]  T. Regad.  Targeting RTK Signaling Pathways in Cancer , 2015, Cancers.

[4]  J. Ji,et al.  BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers , 2015, Molecular Cancer Therapeutics.

[5]  Yu Sun,et al.  Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis , 2015, Journal of receptor and signal transduction research.

[6]  S. Fais,et al.  Proton pump inhibitors while belonging to the same family of generic drugs show different anti-tumor effect , 2015, Journal of enzyme inhibition and medicinal chemistry.

[7]  D. Barras,et al.  BRAF Mutation in Colorectal Cancer: An Update , 2015, Biomarkers in cancer.

[8]  Y. Li,et al.  Design, synthesis and evaluation of novel diaryl urea derivatives as potential antitumor agents. , 2014, European journal of medicinal chemistry.

[9]  Tianming Yang,et al.  Functionalized acridin-9-yl phenylamines protected neuronal HT22 cells from glutamate-induced cell death by reducing intracellular levels of free radical species. , 2014, Bioorganic & medicinal chemistry letters.

[10]  Steven A. Spronk,et al.  Conformationally constrained ortho-anilino diaryl ureas: discovery of 1-(2-(1'-neopentylspiro[indoline-3,4'-piperidine]-1-yl)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea, a potent, selective, and bioavailable P2Y1 antagonist. , 2013, Journal of medicinal chemistry.

[11]  San-qi Zhang,et al.  Synthesis and cytotoxic activity of diaryl urea derivatives with a 4-methylpiperazinylcarbonyl moiety , 2013, Medicinal Chemistry Research.

[12]  Lixin Wu,et al.  Design, synthesis and evaluation of 1,2-benzisothiazol-3-one derivatives as potent caspase-3 inhibitors. , 2013, Bioorganic & medicinal chemistry.

[13]  S. Laufer,et al.  Design, synthesis and characterization of N', N"-diaryl ureas as p38 kinase inhibitors. , 2013, Medicinal chemistry (Shariqah (United Arab Emirates)).

[14]  Sean Ekins,et al.  Novel diaryl ureas with efficacy in a mouse model of malaria. , 2013, Bioorganic & medicinal chemistry letters.

[15]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[16]  J. Emile,et al.  Prognostic Value of BRAFV600 Mutations in Melanoma Patients After Resection of Metastatic Lymph Nodes , 2012, Annals of Surgical Oncology.

[17]  Ashish P. Keche,et al.  A novel pyrimidine derivatives with aryl urea, thiourea and sulfonamide moieties: synthesis, anti-inflammatory and antimicrobial evaluation. , 2012, Bioorganic & medicinal chemistry letters.

[18]  J. Hah,et al.  New diarylureas and diarylamides possessing acet(benz)amidophenyl scaffold: design, synthesis, and antiproliferative activity against melanoma cell line. , 2012, Bioorganic & medicinal chemistry letters.

[19]  Dorothy M. K. Keefe,et al.  Tumor control versus adverse events with targeted anticancer therapies , 2012, Nature Reviews Clinical Oncology.

[20]  M. Herlyn,et al.  Targeting BRAF in Advanced Melanoma: A First Step toward Manageable Disease , 2011, Clinical Cancer Research.

[21]  E. Barreiro,et al.  Molecular hybridization: a useful tool in the design of new drug prototypes. , 2007, Current medicinal chemistry.

[22]  U. Rapp,et al.  Raf kinases: Oncogenesis and drug discovery , 2006, International journal of cancer.

[23]  René Thomsen,et al.  MolDock: a new technique for high-accuracy molecular docking. , 2006, Journal of medicinal chemistry.

[24]  J. McCubrey,et al.  Modulation of Raf/MEK/ERK kinase activity does not affect the chemoresistance profile of advanced prostate cancer cells. , 2005, International journal of oncology.

[25]  M. Baba,et al.  Orally active CCR5 antagonists as anti-HIV-1 agents. Part 3: Synthesis and biological activities of 1-benzazepine derivatives containing a sulfoxide moiety. , 2005, Bioorganic & medicinal chemistry.

[26]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[27]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[28]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[29]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[30]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.